Rhenium-(Re-186)-obisbemeda [Re-186-nanoliposome] (186RNL) Phase 2 for recurrent glioblastoma (rGBM) via Convection Enhance Delivery [CED] (SNO 2023) - Nov 11, 2023 - Abstract #CTNI-49; Pres time: Nov 17, 2023; 07:30 PM - 09:30 PM; Location: Exhibit Hall A/B; "186RNL therapy resulted in a dose and volume dependent impact on OS without significant toxicity. Based on these data, the Cohort 6 non-DLT dose advanced to Phase 2. Study progress will be reported."
P2 data • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor
|
|
Andrew J. Brenner; Joel Michalek; Melissa Moore; Marc Hedrick; Ande Bao; William T. Phillips; Toral R. Patel; Jeffrey S. Weinberg; John Floyd
|